Positive auto-regulation of MYCN in human neuroblastoma

Biochemical and Biophysical Research Communications

Volumn 390, Issue 1, 2009, Pages 21-26

  Suenaga, Yusuke ^a,b   Kaneko, Yoshiki ^a,b   Matsumoto, Daisuke ^a,c   Hossain, Mohammad Shamim ^a   Ozaki, Toshinori ^a,b   Nakagawara, Akira ^a,b  

^a CHIBA CANCER CENTER   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c SUZUKA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

All trans retinoic acid (ATRA); MYCN; Neuroblastoma; Neuronal differentiation; Positive auto regulation

Indexed keywords

LUCIFERASE; MESSENGER RNA; PROTEIN; PROTEIN MYCN; RETINOIC ACID; UNCLASSIFIED DRUG;

ARTICLE; AUTOREGULATION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DOWNSTREAM PROCESSING; E BOX ELEMENT; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INTRON; NERVE CELL DIFFERENTIATION; NEUROBLASTOMA CELL; ONCOGENE; PRIORITY JOURNAL;

CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; E-BOX ELEMENTS; GENE EXPRESSION REGULATION; GENOME, HUMAN; HOMEOSTASIS; HUMANS; NEUROBLASTOMA; NEUROGENESIS; NEURONS; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; TRETINOIN;

EID: 70349975704     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.09.044     Document Type: Article

References (34)

1. Brodeur G.M. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer 3 (2003) 203-216
2. Nakagawara A., and Ohira M. Comprehensive genomics linking between neural development and cancer: neuroblastoma as a model. Cancer Lett. 204 (2004) 213-224
3. Tomioka N., Oba S., Ohira M., Misra A., Fridlyand J., Ishii S., Nakamura Y., Isogai E., Hirata T., Yoshida Y., Todo S., Kaneko Y., Albertson D.G., Pinkel D., Feuerstein B.G., and Nakagawara A. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature. Oncogene 27 (2008) 441-449
4. Brodeur G.M., Seeger R.C., Schwab M., Varmus H.E., and Bishop J.M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224 (1984) 1121-1124
5. Schwab M., Ellison J., Busch M., Rosenau W., Varmus H.E., and Bishop J.M. Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. Proc. Natl. Acad. Sci. USA 81 (1984) 4940-4944
6. Seeger R.C., Brodeur G.M., Sather H., Dalton A., Siegel S.E., Wong K.Y., and Hammond D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N. Engl. J. Med. 313 (1985) 1111-1116
7. Weiss W.A., Aldape K., Mohapatra G., Feuerstein B.G., and Bishop J.M. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 16 (1997) 2985-2995
8. Meyer N., and Penn L.Z. Reflecting on 25 years with MYC. Nat. Rev. Cancer 8 (2008) 976-990
9. Eilers M., and Eisenman R.N. Myc's broad reach. Genes Dev. 22 (2008) 2755-2766
10. Fredlund E., Ringnér M., Maris J.M., and Påhlman S. High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc. Natl. Acad. Sci. USA 105 (2008) 14094-14099
11. Matsushima H., and Bogenmann E. Expression of trkA cDNA in neuroblastomas mediates differentiation in vitro and in vivo. Mol. Cell. Biol. 13 (1993) 7447-7456
12. Thiele C.J., Reynolds C.P., and Israel M.A. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 313 (1985) 404-406
13. Bogenmann E., Torres M., and Matsushima H. Constitutive N-myc gene expression inhibits trkA mediated neuronal differentiation. Oncogene 10 (1995) 1915-1925
14. Peverali F.A., Orioli D., Tonon L., Ciana P., Bunone G., Negri M., and Della-Valle G. Retinoic acid-induced growth arrest and differentiation of neuroblastoma cells are counteracted by N-myc and enhanced by max overexpressions. Oncogene 12 (1996) 457-462
15. Negroni A., Scarpa S., Romeo A., Ferrari S., Modesti A., and Raschellà G. Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line. Cell Growth Differ. 2 (1991) 511-518
16. Kang J.H., Rychahou P.G., Ishola T.A., Oiao J., Evers B.M., and Chung D.H. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. Biochem. Biophys. Res. Commun. 351 (2006) 192-197
17. Lotan R. Retinoids in cancer chemoprevention. FASEB J. 10 (1996) 1031-1039
18. Matthay K.K., Villablanca J.G., Seeger R.C., Stram D.O., Harris R.E., Ramsay N.K., Swift P., Shimada H., Black C.T., Brodeur G.M., Gerbing R.B., and Reynolds C.P. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N. Engl. J. Med. 341 (1999) 1165-1173
19. Strieder V., and Lutz W. Regulation of N-myc expression in development and disease. Cancer Lett. 180 (2002) 107-109
20. Strieder V., and Lutz W. E2F proteins regulate MYCN expression in neuroblastomas. J. Biol. Chem. 278 (2003) 2983-2989
21. Inge T.H., Casson L.K., Priebe W., Trent J.O., Georgeson K.E., Miller D.M., and Bates P.J. Importance of Sp1 consensus motifs in the MYCN promoter. Surgery 132 (2002) 232-238
22. Kramps C., Strieder V., Sapetschnig A., Suske G., and Lutz W. E2F and Sp1/Sp3 synergize but are not sufficient to activate the MYCN gene in neuroblastomas. J. Biol. Chem. 279 (2004) 5110-5117
23. Kanemaru K.K., Tuthill M.C., Takeuchi K.K., Sidell N., and Wada R.K. Retinoic acid induced downregulation of MYCN is not mediated through changes in Sp1/Sp3. Pediatr. Blood Cancer 50 (2008) 806-811
24. Hossain M.S., Ozaki T., Wang H., Nakagawa A., Takenobu H., Ohira M., Kamijo T., and Nakagawara A. N-MYC promotes cell proliferation through a direct transactivation of neuronal leucine-rich repeat protein-1 (NLRR1) gene in neuroblastoma. Oncogene 27 (2008) 6075-6082
25. Dráberová E., Lukás Z., Ivanyi D., Viklický V., and Dráber P. Expression of class III beta-tubulin in normal and neoplastic human tissues. Histochem. Cell Biol. 109 (1998) 231-239
26. Tucholski J., Lesort M., and Johnson G.V. Tissue transglutaminase is essential for neurite outgrowth in human neuroblastoma SH-SY5Y cells. Neuroscience 102 (2001) 481-491
27. Schwab M. MYCN in neuronal tumours. Cancer Lett. 204 (2004) 179-187
28. Kohl N.E., Gee C.E., and Alt F.W. Activated expression of the N-myc gene in human neuroblastomas and related tumors. Science 226 (1984) 1335-1337
29. Wada R.K., Seeger R.C., Brodeur G.M., Einhorn P.A., Rayner S.A., Tomayko M.M., and Reynolds C.P. Human neuroblastoma cell lines that express N-myc without gene amplification. Cancer 72 (1993) 3346-3354
30. Hurlin P.J. N-Myc functions in transcription and development. Birth Defects Res. C Embryo Today 75 (2005) 340-352
31. Zimmerman K., Legouy E., Stewart V., Depinho R., and Alt F.W. Differential regulation of the N-myc gene in transfected cells and transgenic mice. Mol. Cell. Biol. 10 (1990) 2096-2103
32. Hiller S., Breit S., Wang Z.Q., Wagner E.F., and Schwab M. Localization of regulatory elements controlling human MYCN expression. Oncogene 6 (1991) 969-977
33. Niizuma H., Nakamura Y., Ozaki T., Nakanishi H., Ohira M., Isogai E., Kageyama H., Imaizumi M., and Nakagawara A. Bcl-2 is a key regulator for the retinoic acid-induced apoptotic cell death in neuroblastoma. Oncogene 25 (2006) 5046-5055
34. Wada R.K., Seeger R.C., Reynolds C.P., Alloggiamento T., Yamashiro J.M., Ruland C., Black A.C., and Rosenblatt J.D. Cell type-specific expression and negative regulation by retinoic acid of the human N-myc promoter in neuroblastoma cells. Oncogene 7 (1992) 711-717